Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 3Recruiting 2Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Brain Neoplasms 13Glioblastoma 6Glioma 5Epilepsy 5Stroke 3Pheochromocytoma 3Parkinson Disease 3Paraganglioma 3Neuroblastoma 3Neoplasms 3Speech 2Neurofibromatosis 1 2Neurofibroma 2Multiple Sclerosis 2Migraine Disorders 2Lung Neoplasms 2Diabetes Mellitus 2Carcinoma, Non-Small-Cell Lung 2Amyotrophic Lateral Sclerosis 2Adrenal Gland Neoplasms 2Tinnitus 1Thyroid Neoplasms 1Tension-Type Headache 1Stress Disorders, Post-Traumatic 1Squamous Cell Carcinoma of Head and Neck 1Spinal Stenosis 1Spinal Cord Injuries 1Skin Neoplasms 1Restless Legs Syndrome 1Renal Insufficiency, Chronic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × Adenoviridae Infections × CNS × Clear all
NCT06763965 2026-03-23

Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.

Beijing Bio-Targeting Therapeutics Technology Co., Ltd

Phase 1/2 Enrolling by invitation
30 enrolled
CNS

Adenoviridae Infections, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡